Unpacking the Definitive Truth: COVID-19 Vaccines and MS

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies. As COVID-19 variants continue to evolve, vaccination remains a critical component of care for individuals with multiple sclerosis (MS), especially those receiving immunosuppressive therapies, according to a new review highlighting the latest evidence supporting vaccination safety and effectiveness in this vulnerable population.1

The multinational team of experts aimed to clarify lingering concerns around vaccine timing, disease-modifying therapies (DMTs), and long-term protection while also offering practical guidance for US health care providers and policymakers. The review, published in Neurology Neuroimmunology & Neuroinflammation, emphasized that vaccination remains one of the most effective tools to prevent severe COVID-19 outcomes—especially for patients receiving DMTs.

“Although earlier studies produced mixed messages about infection risks among patients with MS (PwMS), this analysis clarified that the benefits of vaccination significantly outweigh the risks, even in patients on immunosuppressive regimens.”


Monschein T, Zrzavy T, Rommer PS, et al., Neurology Neuroimmunology & Neuroinflammation

Dispelling Old Doubts: What Really Increases Risk in MS?

According to the National Multiple Sclerosis Society, PwMS are not inherently at greater risk for contracting COVID-19 or experiencing severe illness. However, the risk *does* increase for those with specific factors. This new study clarifies which factors truly matter, moving beyond broad assumptions to pinpoint genuine vulnerabilities.

These risk factors include older age, Black race, male sex, obesity, progressive MS, or additional chronic conditions. The use of specific disease-modifying therapies (DMTs) like anti-CD20 treatments can also elevate risk.

💡 Key Insight

“COVID-19 vaccination should be administered following national recommendations and especially also in PwMS, [several individual and health] factors…should be taken into account. Comparatively, these factors are also very important for those who are vaccine skeptical because the risk of potential COVID-19 disease may be significantly increased in at-risk individuals.”

Decoding DMTs and Your Vaccine Response: What This Means for You

  1. 1

    Strong Efficacy & Favorable Safety Profile Confirmed

    Researchers reviewed extensive clinical trial data, observational studies, and registry information, aligning findings with major health organizations like the CDC and European Medicines Agency. The conclusion is clear: mRNA and vector-based vaccines show strong efficacy against severe disease, including new variants, and maintain favorable safety profiles in PwMS.

  2. 2

    Rare Adverse Events Are Indeed Rare

    Concerns about rare adverse events like myocarditis or Guillain-Barré syndrome were addressed. These events were most often seen in young men and remained uncommon. Crucially, the study found that vaccination did not appear to increase the risk of MS relapse or exacerbate disease activity.

  3. 3

    Optimizing Protection: Timing is Key

    One key insight highlights how certain DMTs, particularly B-cell–depleting therapies like anti-CD20 agents, might blunt the antibody response. However, patients typically still generate a strong cellular immune response, providing meaningful protection. The review emphasizes “hybrid immunity” (prior infection + vaccination) for the most robust defense and recommends aligning vaccination timing with DMT dosing schedules to improve immune response. This means working closely with your neurologist to find the optimal schedule for your personal treatment plan.